BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25749740)

  • 1. Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance).
    Dueck AC; Singh J; Atherton P; Liu H; Novotny P; Hines S; Loprinzi CL; Perez EA; Tan A; Burger K; Zhao X; Diekmann B; Sloan JA;
    Osteoporos Int; 2015 Jul; 26(7):1971-7. PubMed ID: 25749740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
    Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
    Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
    Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
    Eastell R; Lang T; Boonen S; Cummings S; Delmas PD; Cauley JA; Horowitz Z; Kerzberg E; Bianchi G; Kendler D; Leung P; Man Z; Mesenbrink P; Eriksen EF; Black DM;
    Osteoporos Int; 2010 Jul; 21(7):1277-85. PubMed ID: 19802508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
    Paggiosi MA; Peel N; McCloskey E; Walsh JS; Eastell R
    Osteoporos Int; 2014 Dec; 25(12):2729-41. PubMed ID: 25074351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
    Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis.
    Zhu HM; Qin L; Garnero P; Genant HK; Zhang G; Dai K; Yao X; Gu G; Hao Y; Li Z; Zhao Y; Li W; Yang J; Zhao X; Shi D; Fuerst T; Lu Y; Li H; Zhang X; Li C; Zhao J; Wu Q; Zhao SJ
    Osteoporos Int; 2012 Apr; 23(4):1317-27. PubMed ID: 21505910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal changes in bone mineral density and trabecular bone score following yearly zoledronic acid infusion in postmenopausal osteoporosis-a retrospective-prospective study from southern India.
    Sooragonda B; Cherian KE; Jebasingh FK; Dasgupta R; Asha HS; Kapoor N; Thomas N; Paul TV
    Arch Osteoporos; 2019 Jul; 14(1):79. PubMed ID: 31321603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy.
    Kalder M; Kyvernitakis I; Albert US; Baier-Ebert M; Hadji P
    Osteoporos Int; 2015 Jan; 26(1):353-60. PubMed ID: 25381047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment.
    Anastasilakis AD; Polyzos SA; Makras P; Gkiomisi A; Savvides M; Papatheodorou A; Terpos E
    Osteoporos Int; 2013 Jul; 24(7):2127-32. PubMed ID: 23124716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
    Cairoli E; Eller-Vainicher C; Ulivieri FM; Zhukouskaya VV; Palmieri S; Morelli V; Beck-Peccoz P; Chiodini I
    Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.
    Hines SL; Mincey B; Dentchev T; Sloan JA; Perez EA; Johnson DB; Schaefer PL; Alberts S; Liu H; Kahanic S; Mazurczak MA; Nikcevich DA; Loprinzi CL
    Breast Cancer Res Treat; 2009 Oct; 117(3):603-9. PubMed ID: 19214743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study.
    Leslie WD; Martineau P; Bryanton M; Lix LM
    Osteoporos Int; 2019 Jul; 30(7):1445-1453. PubMed ID: 31016351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
    Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
    Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
    Brown JP; Roux C; Ho PR; Bolognese MA; Hall J; Bone HG; Bonnick S; van den Bergh JP; Ferreira I; Dakin P; Wagman RB; Recknor C
    Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
    Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
    Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer.
    Leal T; Tevaarwerk A; Love R; Stewart J; Binkley N; Eickhoff J; Parrot B; Mulkerin D
    Clin Breast Cancer; 2010 Dec; 10(6):471-6. PubMed ID: 21147691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis.
    Kendler DL; Palacios S; Cox DA; Stock J; Alam J; Dowsett SA; Zanchetta J
    Osteoporos Int; 2012 Mar; 23(3):1091-101. PubMed ID: 21374068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.